Roche's Bluetooth-enabled meter gives patients the option to bypass frequent trips to the clinic in favor of doing anticoagulation testing at home.
This week's news includes Alere, Fulget Diagnostics, Trovagene, Great Basic Scientific, Interleukin, and Danaher.
Abbott CEO Miles White said that while Alere is a bit of a fixer upper, he is pleased to have a resolution to issues surrounding the proposed acquisition.
The firms also dropped their lawsuits against each other, and said they expect to complete the merger by the end of the third quarter.
The New York Stock Exchange gave Alere an additional six months to file its 2016 annual report, but it also said it could commence delisting proceedings at any time.
Researchers and companies move to develop blood-based tests for concussion, according to Scientific American.
The firm said that its test is the first on the market to detect RSV infection at the point of care in 13 minutes or less.
The firm wants to develop a test that can provide objective, reliable, and rapid information so that clinicians can make critical decisions in circumstances of high uncertainty.
The FDA granted Abbott Emergency Use Authorization for the assay in serum, plasma, and urine in November.
Companies with diverse infectious disease diagnostic technology offerings said that molecular methods are complementary to, not competitive with traditional diagnostics.
A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.
LiveScience reports that a novel mutation in the LPL gene was uncovered in three siblings with very high triglyceride levels.
The president of Nankai University is embroiled in a data manipulation scandal, the South China Morning Post reports.
In PNAS this week: cytotoxic CD4 T cell signature in supercentenarians, evolutionary history of beetles, and more.